Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SPHS
CUSIPN/A
Phone858-777-1760
Debt
Debt-to-Equity Ratio-3.97
Current Ratio3.57
Quick Ratio3.57
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.25 per share
Price / Book10.68
Profitability
EPS (Most Recent Fiscal Year)($0.40)
Net Income$-8,620,000.00
Net MarginsN/A
Return on Equity-267.35%
Return on Assets-59.46%
Miscellaneous
Employees6
Outstanding Shares30,110,000
Market Cap$80.40 million
Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions
What is Sophiris Bio's stock symbol?
Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."
How were Sophiris Bio's earnings last quarter?
Sophiris Bio Inc (NASDAQ:SPHS) announced its quarterly earnings results on Tuesday, August, 14th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.05. View Sophiris Bio's Earnings History.
When is Sophiris Bio's next earnings date?
What price target have analysts set for SPHS?
2 brokers have issued 1 year price objectives for Sophiris Bio's stock. Their forecasts range from $8.00 to $10.00. On average, they expect Sophiris Bio's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 237.1% from the stock's current price. View Analyst Price Targets for Sophiris Bio.
What is the consensus analysts' recommendation for Sophiris Bio?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sophiris Bio.
What are Wall Street analysts saying about Sophiris Bio stock?
Here are some recent quotes from research analysts about Sophiris Bio stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $10 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Sophiris Bio Inc." (9/13/2018)
- 2. Maxim Group analysts commented, "Sophiris announced that the investigation into the patient death in the P2b study of topsalysin in prostate cancer (PC) was unlikely to be related to the drug or the procedure (see note from 6/25). SPHS shares are up ~25% this morning." (8/29/2018)
Who are some of Sophiris Bio's key competitors?
Some companies that are related to Sophiris Bio include Sienna Biopharmaceuticals (SNNA), Concert Pharmaceuticals (CNCE), MEI Pharma (MEIP), Innate Pharma (IPHYF), BIOFRONTERA AG/ADR (BFRA), Paratek Pharmaceuticals (PRTK), Seres Therapeutics (MCRB), Acer Therapeutics (ACER), Aratana Therapeutics (PETX), ProMetic Life Sciences (PFSCF), Axovant Sciences (AXON), Affimed (AFMD), Tocagen (TOCA), CELYAD SA/ADR (CYAD) and Mersana Therapeutics (MRSN).
Who are Sophiris Bio's key executives?
Sophiris Bio's management team includes the folowing people:
- Mr. Randall E. Woods, CEO, Pres & Director (Age 66)
- Mr. Peter T. Slover, Chief Financial Officer (Age 43)
- Dr. Allison J. Hulme, COO, Head of R&D and Director (Age 55)
- Dr. Samuel R. Denmeade M.D., Chief Scientific Officer and Member of the Scientific Advisory Board
- Dr. James Joseph Beesley BSc, DC, Sr. Director of Investor Relations (Age 46)
Who are Sophiris Bio's major shareholders?
Which major investors are buying Sophiris Bio stock?
How do I buy shares of Sophiris Bio?
Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sophiris Bio's stock price today?
One share of SPHS stock can currently be purchased for approximately $2.67.
How big of a company is Sophiris Bio?
Sophiris Bio has a market capitalization of $80.40 million. The biopharmaceutical company earns $-8,620,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe.
What is Sophiris Bio's official website?
How can I contact Sophiris Bio?
Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]
MarketBeat Community Rating for Sophiris Bio (NASDAQ SPHS)
MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe SPHS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days.
